Company profile
Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Tuxobertinib | phase1 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04209465 | phase1 | terminated | 2019-12-19 | 2022-09-02 | Black Diamond Therapeutics, Inc. | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. |
| NCT05256290 | phase1_2 | active_not_recruiting | 2022-03-31 | 2025-11-03 | Black Diamond Therapeutics, Inc. | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations |
| NCT07326566 | phase2 | recruiting | 2026-05-05 | 2028-11-01 | Black Diamond Therapeutics, Inc. | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII |
FDA applications (0)
No records yet.